Full donor whole blood chimerism can predict superior progression free survival in reduced intensity alemtuzumab based conditioning transplant recipients for high risk MDS and AML ; a single centre experience
Kanellopoulos, A. Saeed, M. Eden, D. Qureshi, I. Cain, L. Khawaja, J. Kaparou, M. Xenou, E. Borg, A. Arbuthnot, C.
Kanellopoulos, A.
Saeed, M.
Eden, D.
Qureshi, I.
Cain, L.
Khawaja, J.
Kaparou, M.
Xenou, E.
Borg, A.
Arbuthnot, C.
Abstract
Physicians Poster Sessions abstract P246 of the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, Valencia, Spain, 3–6 April 2016.
MIDER Authors
Affiliations
Heart of England NHS Trust; South Warwickshire University NHS Foundation Trust; New Cross Hospital, Wolverhampton
Citations
Altmetric:
Date
2016-03-21
Type
Conference Output
Subject
Collections
Citation
Kanellopoulos A, Saeed M, Eden D, Qureshi I, Cain L, Khawaja J, Kaparou M, Xenou E, Borg A, Arbuthnot C, Randall K, Lee S, Holder K, Bratby L, Kishore B, Lovell R, Paneesha S, Nikolousis E. Full donor whole blood chimerism can predict superior progression free survival in reduced intensity alemtuzumab based conditioning transplant recipients for high risk MDS and AML; a single centre experience. Bone Marrow Transplant. 2016 Mar;51(Suppl 1):S242-S243. doi: 10.1038/bmt.2016.48.